BHC$6.94
$6.95
Chart
Performance
Key Stats
AI BHC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBausch Health Companies Inc. shows a mixed investment profile. While its fundamental valuation and growth metrics present opportunities, recent performance trends and technical indicators suggest caution. The company's significant debt load and inconsistent profitability are key risk factors.
Thematic
Bausch Health operates in diverse healthcare segments, including eye health, dermatology, and gastroenterology. The company's exposure to established markets offers stability, but it lacks strong positioning in high-growth thematic areas like AI or next-generation biotechnology.
Fundamental
Bausch Health demonstrates revenue growth and improved profitability in the latest periods, but a substantial debt burden and negative equity remain significant concerns. The current valuation appears attractive on a P/S basis but is less compelling when considering profitability metrics.
Technical
The stock shows positive short-term momentum, trading above key moving averages, but faces resistance and has mixed oscillator signals. A break above recent resistance levels would strengthen the bullish outlook.
| Factor | Score |
|---|---|
| Healthcare Sector Trends | 70 |
| Innovation & R&D Focus | 55 |
| Market Position | 65 |
| ESG Considerations | 50 |
| Factor | Score |
|---|---|
| Valuation | 85 |
| Valuation | 20 |
| Profitability | 30 |
| Growth | 70 |
| Balance Sheet Health | 10 |
| Cash Flow | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Moving Averages | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Price Momentum
The stock price has increased by 1.95% today, and has shown positive performance over the last 5 days (+7.28%) and 1 month (+5.77%).
Potential for Growth
The company has a positive beta of 0.41, suggesting lower volatility than the broader market. The average volume also indicates consistent investor interest.
Bearish Points (8)
Persistent Net Losses
The company has reported net losses for the trailing twelve months (-$50M), 2023 (-$592M), and 2024 (-$46M), indicating ongoing profitability challenges.
Negative Earnings Per Share (EPS)
The EPS (TTM) is -$0.12, and quarterly EPS reports show consistent negative surprises or estimates far exceeding reported figures, suggesting the company is not generating profit per share.
Calendar
November 2010
10
Ex-Dividend Date
July 2025
31
Next Earnings Date
H: $1.10
A: $0.94
L: $0.82
H: 2.53B
A: 2.48B
L: 2.45B
Profile
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Seasonals
Price Target
7.08 USD
The 39 analysts offering 1 year price forecasts for BHC have a max estimate of 10.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct spin-off from BHC in 2022, maintaining significant operational and market overlap in global eye health, including vision care, pharmaceuticals, and surgical products.
Weight: 95
Major global competitor in eye care, offering surgical equipment, vision care products (contact lenses, solutions), and ocular pharmaceuticals, directly competing with Bausch + Lomb's former core business.
Weight: 92
Significant player in vision care through CooperVision (contact lenses) and CooperSurgical (women's healthcare), presenting direct competition in a key segment of BHC's historical focus.
Weight: 90
Diversified global healthcare giant with a substantial presence in pharmaceuticals, medical devices, and consumer health, including Acuvue contact lenses, overlapping with BHC's broader portfolio.